To better characterize the TME, we investigated by IHC the expression of three immune checkpoint molecules (CTLA-4, PD-1, and PD-L1), which are the targets of ICI therapies approved by the FDA [18], in different compartments of the liver in the immune-high and immune-low HCC subtypes. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.